Tyrosinemia type III is an autosomal recessive disorder caused by the defi ciency of 4-hydroxyphenylpyruvate dioxygenase (4-HPPD). It is characterized by elevated levels of blood tyrosine and massive excretion of its derivatives into the urine. Clinical fi ndings of tyrosinemia type III include neurological symptoms and mental retardation. Only a few patients presenting with this disease have been described, and the clinical phenotype remains variable and unclear. We present a case, who was admitted to the hospital at the age of 4 months for recurrent seizures. Two months later, she was admitted again with status epilepticus. Laboratory data showed increased level of tyrosine in the blood. She was treated with a diet low in tyrosine and phenylalanine and anamix formula that leading to catch-up growth and improvement of her symptoms. Plasma tyrosine level dropped to normal values. In any child who presents with the neurologic symptom, some rare diagnosis like tyrosinemia type III should be considered.
Introduction
Tyrosinemia type III is a rare disorder. Only a few patients have been described. Tyrosine is a precursor of dopamine, norepinephrine, epinephrine, melanin, and thyroxine. [1] This autosomal recessive disease is caused by the defi ciency of 4-hydroxyphenylpyruvate dioxygenase [2] [3] [4] that is mainly expressed in neurons, neutrophils, kidney, and liver cells. [5] It catalyzes the reaction of 4-hydroxyphenylpyruvic acid to homogentisic acid [ Figure 1 ]. [6, 7] The disease is characterized by increased level of blood tyrosine and massive excretion of its derivatives into the urine. [8] Excessive NO release can also participate in neuronal damage. [2] Age of presentation is from 1 to 17 months. [1] The clinical phenotype remains variable and unclear. [5] Neurological symptoms include developmental delay, behavioral disturbance, seizures, microcephaly, ataxia, tremor, hypotonia, absent deep tendon refl exes, [2, 5, 9, 10] here, we present a case of tyrosinemia type III with status epilepticus.
Case Report
This patient was a 21-month-old girl, who was born at term with birth weight 2250 g and head circumference 33 cm following a pregnancy with polyhydramnios. The patient had no perinatal problem. She was the second child of No consanguineous parents. The fi rst sibling was a 4-year-old boy who is healthy and normally developed. She was admitted to Pediatric Emergency Department at 4 mont hs of age for recurrent seizure. Two months later she was admitted again with status epilepticus. Her seizure controlled with antiepileptic drugs. We did not fi nd any reason for status epilepticus in routine lab tests, cerebrospinal fl uid analysis; brain computed tomography scan, brain magnetic resonance imaging, and blood gas analysis. All of them were normal.
Metabolic investigations showed increased level of tyrosine in the blood (737 μmol/l and 915 μmol/l) in 2 consecutive time, (normal range 88-204 μmol/l). The levels of 4-hydroxyphenyl lactic acid (1710 mmol/mol creatinine with normal <5.3) and 4-hydroxyphenyl pyruvic acid (2184 mmol/mol creatinine with normal <4.9) in the urine were elevated, without marked elevation of succinylacetone. Kidney and liver functions were normal. Clinical fi ndings and biological abnormalities were suggestive of tyrosinemia type III and were treated with 
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For reprints contact: reprints@medknow.com a diet low in tyrosine, phenylalanine, and anamix formula plus ascorbic acid supplementation (50 mg/day in two doses) that leading to catch-up growth and improvement of her symptoms. Plasma tyrosine level dropped to normal values. Now her mental status is mildly delayed.
Discussion
To our knowledge, only a few patients presenting with this disease have been described in the literature, and none of them presented with status epilepticus.
Most of the reported patients have had neurological symptoms after the neonatal period while others detected by neonatal screening have been asymptomatic. Like our patient all have had normal liver and renal function and none has skin or eye abnormalities. [11] The most common long-term complication is intellectual impairment, found in 75% of patients. In 2008, a patient with tyrosinemia type III was described with autism and mental retardation . [11] Mild hypertyrosinemia may be offered as typical clinical features of the disease. [8] Asymptomatic infants with 4-HPPD defi ciency have been identifi ed by neonatal screening for hypertyrosinemia. [1] Our patient presented with seizure and status epilepticus, and neurological abnormalities. Similar to our patient Endo et al. reported a patient with seizure, mental retardation, and neurological abnormalities. In another study, Cerone et al. reported a patient with intermittent ataxia. [3] The high tyrosine concentration in an otherwise normal amino acid profi le has been found in patients presenting with neurological symptoms. [12] The diagnosis is suspected in children with sustained moderate increases in plasma levels of tyrosine (typically 350-700 μmole/L on a normal diet) and massive excretion of its derivatives, 4-hydroxyphenyl pyruvic acid, 4-hydroxyphenyl lactic, and 4-hydroxyphenyl acetic acid into in urine. [1] One of the important factors for defi nitive diagnosis is genetic study or assay the activity of a 4-HPPD enzyme in liver biopsy. [1] That is what we could not do it and can be a limitation of our study.
In 2001 on a review of 13 patients, fi ve were detected by neonatal screening, two of which were free of any symptoms, with a normal development at 13 months, and 5.4 years, respectively, following a low tyrosine and phenylalanine diet; the three other patients showed mild intellectual impairment. Eight out of 13 patients were diagnosed after the neonatal period because of neurologic signs, that one of them showing a normal development at the age of 17 years, [13] in contrast to our patient that the fi rst neurological signs were started at 4 months of age. Clinical and biochemical fi ndings in patients with a 4-HPPD defi ciency in previous and present studies illustrated in Table 1 .
In favor of our patient long-term treatment with a tyrosine-restricted diet led to control of seizure disorder.
In the last reported cases, improvement of signs, symptoms, and psychomotor function were observed with a restricted diet. [5] However, D'Eufemia et al. reported that their patient showed normal psychomotor development and no clinical signs in spite of a normal diet. [2] In our patient, mild mental retardation remained, similar to the reported case by Heylen et al. [5] Their patient's language skills and autistic behavior improved by using a tyrosine-restricted diet while no changes were made in the mental retardation. [5] The effects of therapeutic interventions by using a low-protein diet are still unknown, and it is not yet clear whether lowering plasma tyrosine levels is able to alter the natural history of the disease in spite of this fact that it is recommended to treat these patients with a tyrosine-and phenylalanine-restricted diet. [5] As treatment with 2-(2-nitro-4-trifl uoromethylbenzoyl)-1,3-ciclohexanedione (NTBC) in patients with tyrosinemia type I shifts the metabolic block from fumarylacetoacetate hydrolase to p-hydroxyphenylpyruvate dioxygenase or from tyrosinemia type I to tyrosinemia type III, treatment with NTBC must be supplemented by dietary treatment with a phenylalanine-and tyrosine-reduced diet, which is the rational approach to treatment in tyrosinemias type II and III. [14] NTBC do not approve for the treatment of 
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